Drug Trial Radar · NCT05045248
Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis
Last checked: Nov 19, 2026Latest source record: Sep 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jun 1, 2020
Primary completion
Apr 15, 2021
Study completion Apr 15, 2021
Sponsor
- Lead sponsor
- American University of Beirut Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.
Conditions
- Myasthenia Gravis
- Ocular Myasthenia Gravis
Interventions
Apraclonidine Hcl 0.5% Oph SolnDrug
Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in palpebral fissure height (PF)Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
- Change in marginal reflex distance-1 (MRD1)Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
- Change in marginal reflex distance-2 (MRD2)Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
- Change in levator function (LF)Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
American University of Beirut Medical Center
Beirut, Lebanon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.